ImmunoGen, Inc. Announces Clinical Data Presentations at the 52nd ASH Annual Meeting and Exposition
17 November 2010 - 10:31PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops targeted antibody-based anticancer products, today
announced that three presentations of clinical data for compounds
employing its Targeted Antibody Payload (TAP) technology will be
made at the 52nd ASH Annual Meeting and Exposition to be held in
Orlando, Florida, December 4-7, 2010.
“Findings from three clinical trials with two TAP compounds are
being reported at ASH this year, reflecting the start in the rapid
growth in the number of trials underway with TAP compounds that
began last year,” commented Daniel Junius, President and CEO.
“Initial data will be reported from the first trial to assess
IMGN901 used as part of a combination regimen – in this case, to
treat multiple myeloma – which will complement the trial we’re
starting that assesses it in combination with approved therapies to
treat small-cell lung cancer. Updated data will be reported from
the IMGN901 monotherapy trial as well as from the first trial
conducted with Biotest’s TAP compound, BT-062, which is now being
assessed, as planned, in a second trial using a more frequent
dosing regimen.”
Presentations on Dec. 4 from 5:30-7:30 pm ET in Hall
A3/A4:
- “Phase I Study of Lorvotuzumab
Mertansine (IMGN901) In Combination with Lenalidomide and
Dexamethasone In Patients with CD56-Positive Relapsed or
Relapsed/Refractory Multiple Myeloma – A Preliminary Safety
and Efficacy Analysis of the Combination” (Abstract #1934, Poster
board #I-914).
- “Efficacy Analysis from Phase I Study
of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In
Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma –
A Preliminary Efficacy Analysis” (Abstract #1962, Poster board
#I-942).
Presentation on Dec. 5 from 6:00-8:00 pm ET in Hall
A3/A4:
- “BT062, An Antibody-Drug Conjugate
Directed Against CD138, Shows Clinical Activity In a Phase I Study
in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma”
(Abstract #3060, Poster board #II-940).
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company's expertise in tumor biology, monoclonal antibodies and
potent cancer-cell killing agents. The Company's TAP technology
uses monoclonal antibodies to deliver one of ImmunoGen's
proprietary cancer-cell killing agents specifically to tumor cells.
There are currently seven TAP compounds in the clinic, with a
wealth of clinical data reported with the technology. ImmunoGen’s
collaborative partners include Amgen, Bayer Schering Pharma, Biogen
Idec, Biotest, Genentech (a member of the Roche Group), Novartis,
and sanofi-aventis. The most advanced compound using ImmunoGen's
TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing
through the Company's collaboration with Genentech. More
information about ImmunoGen can be found at www.immunogen.com.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including IMGN901 and BT-062, that
include risks related to uncertainties around preclinical and
clinical studies conducted and their results. A review of these
risks can be found in ImmunoGen’s Annual Report on Form 10-K for
the fiscal year ended June 30, 2010 and other reports filed with
the Securities and Exchange Commission.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024